The Prostate Health Index (phi ) Can Help Reduce Unnecessary Prostate BiopsiesThe Prostate Health Index is an FDA approved blood test that can help differentiate prostate cancer from benign conditions in men with elevated PSA. If you've recently been screened for Prostate Cancer and learned you have an Elevated PSA, click the button below to find out if you're a candidate for the Prostate Health Index.
Ask your doctor if you're a candidate. Or you can order this test through an telehealth physician by clicking here. |
Watch Gary's Story About His Elevated PSA
|
Welcome to Our Education Center Where You Will Find Helpful Information About Prostate Cancer & Prostate Cancer Screening
Prostate Health Index Patient Selection Criteria
Male patients may be a candidate for the Prostate Index Test if they are age 50 years and older with an elevated PSA between 4ng/ml and 10ng/ml. Peer-reviewed published studies support the use of Prostate Health Index in men with total PSA values as low as 2 ng/ml (1-4)
The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) Guideline for Prostate Cancer Early Detection as a blood test to improve specificity for prostate cancer detection. (5)
Male patients may be a candidate for the Prostate Index Test if they are age 50 years and older with an elevated PSA between 4ng/ml and 10ng/ml. Peer-reviewed published studies support the use of Prostate Health Index in men with total PSA values as low as 2 ng/ml (1-4)
The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) Guideline for Prostate Cancer Early Detection as a blood test to improve specificity for prostate cancer detection. (5)
References
- Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of Urology. 2011;185(5):1650-1655.
- Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-1169
- Huang YQ, Sun T, Zhong WD, et al. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol 2014;2(4):343-350
- Lepor A, Catalona WJ, Loeb S. The Prostate Health Index: Its Utility In Prostate Cancer Detection. The Urologic Clinics of North America. 2016;43(1):1-6.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2.2018 – April 5, 2018
- https://www.cancer.gov/types/prostate/psa-fact-sheet (Accessed 4.20.19)
- https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html (Accessed 4.2.0.19)